Long-term results of adjuvant imatinib mesylate in localized, high risk, primary gastrointestinal stromal tumor (GIST): The American College of Surgeons Oncology Group (ACOSOG) Z9000 trial
Ronald P DeMatteo1, Karla Ballman*2, Cristina Antonescu*1, Christopher Corless*3, Violetta Kolesnikova*3, Margaret von Mehren*4, Martin McCarter*5, Jeffrey Norton6, Robert Maki*7, Peter WT Pisters8, George Demetri*9, Murray F. Brennan1, Kouros Owzar*10
1Memorial Sloan-Kettering Cancer Center, New York, NY;2Mayo Clinic, Rochester, MN;3Oregon Health Sciences University, Portland, OR;4Fox Chase Cancer Center, Philadelphia, PA;5University of Colorado Denver School of Medicine, Denver, CO;6Stanford University School of Medicine, Stanford, CA;7Mount Sinai School of Medicine, New York, NY;8University of Texas MD Anderson Cancer Center, Houston, TX;9Dana Farber Cancer Institute, Boston, MA;10Duke University, Durham, NC
OBJECTIVE(S): GIST is the most common sarcoma. Surgery is the mainstay for primary GIST, but tumor recurrence is common. GIST typically contains a KIT or PDGFRA mutation and imatinib mesylate (Gleevec) inhibits both associated proteins. We tested whether adjuvant imatinib prolongs overall survival (OS) in GIST.
Back to Annual Meeting Abstracts